Myeloproliferative Neoplasms | Specialty

The OncLive Myeloproliferative Neoplasms condition center is a comprehensive resource for clinical news and expert insights on myeloproliferative neoplasms, including myelofibrosis, polycythemia vera, and essential thrombocythemia. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in myeloproliferative neoplasms.

Roxadustat Misses Mark as Anemia Treatment in Transfusion-Dependent, Lower-risk MDS

May 5th 2023

The phase 3 MATTERHORN trial examining roxadustat as an anemia treatment in patients with transfusion-dependent, lower-risk myelodysplastic syndrome did not meet its primary end point.

Dr Patel on How the Timing of ASCT Affects Post-Transplant Complications in Myelofibrosis

May 4th 2023

Sagar Patel, MD, discusses how the timing of autologous stem cell transplant can affect outcomes in those with myelofibrosis, including the risk of patients developing post-transplant complications.

Individual Patient Factors Drive Treatment Decisions in MPNs

May 4th 2023

Onco-nursing experts highlight the best practices and latest treatment regimens for patients presenting with the 3 most common myeloproliferative neoplasms: myelofibrosis, polycythemia vera, and essential thrombocythemia.

Looking Ahead in Treating Myeloproliferative Neoplasms

April 26th 2023

Shared closing thoughts on the future treatment landscape for myeloproliferative neoplasms, including future and emerging areas of research and remaining areas of unmet need.

Potential Combination Therapy Approaches with Ruxolitinib in Myelofibrosis

April 26th 2023

A review of recent trial data evaluating combination therapy approaches with ruxolitinib in myelofibrosis, including the rationale and potential clinical benefits associated with the use of these emerging strategies.

Selinexor/Ruxolitinib Combo Elicits Sustained Spleen Responses, Improves Symptoms in Myelofibrosis

April 21st 2023

The combination of selinexor at 60 mg and ruxolitinib induced rapid and durable spleen responses and improved symptoms at weeks 12 and 24 in patients with treatment-naïve myelofibrosis, according to updated data from the phase 1 XPORT-MF-034 trial.

Novel Therapies Under Investigation for Myelofibrosis

April 19th 2023

Focused discussion on emerging trial data surrounding novel, investigational therapies for myelofibrosis.

Treatment Sequencing Approaches for Myelofibrosis

April 19th 2023

Expert perspectives on treatment sequencing strategies with JAK inhibitors for myelofibrosis.

Monitoring Strategies in Myelofibrosis

April 12th 2023

Shared insights on monitoring strategies for myelofibrosis, including important considerations for patients receiving treatment with JAK inhibitors.

JAK Inhibitors in Myelofibrosis

April 12th 2023

Panel experts briefly review supporting data for the use of JAK inhibitors in myelofibrosis and discuss the impact of emerging data on the current treatment landscape.

Adding Patient-Specific Comorbidities May Improve Risk Evaluation in Myelofibrosis

April 11th 2023

Adding patient-specific comorbidities improved the prognostic effect of risk prediction models for patients with primary or secondary myelofibrosis, according to findings from an assessment of data collected in Vanderbilt’s Synthetic Derivative and BioVU Biobank comprehensive electronic health record.

Dr Jain on the Use of Haploidentical Donors in Myelofibrosis

April 6th 2023

Tania Jain, MBBS, discusses the use of haploidentical donors in myelofibrosis.

Transplant Therapy in Myelofibrosis

April 5th 2023

Expert perspectives on how to identify and assess patients with myelofibrosis for transplant therapy.

Myelofibrosis: Diagnosis and Prognostic Risk Assessment

April 5th 2023

Comprehensive discussion highlighting diagnostic and molecular testing involved in the diagnosis of myelofibrosis, challenges related to early diagnosis, and consideration factors for assessing prognostic risk.

Imetelstat Displays Early Efficacy in Myelofibrosis; Phase 3 Trial Is Underway

April 4th 2023

The first-in-class telomerase inhibitor imetelstat is poised to expand the myelofibrosis treatment armamentarium should it prove safe and effective in the newly initiated phase 3 IMpactMF trial.

Rusfertide Improves Responses, Meets Primary End Point of REVIVE Trial in Polycythemia Vera

April 3rd 2023

Treatment with rusfertide led to a higher response rate of 69.2% vs 18.5% with placebo in patients with polycythemia vera, meeting the primary end point of the phase 2 REVIVE trial.

Myelofibrosis: Classification, Risk Factors, and Biomarkers

March 29th 2023

Shared insight on classification, risk factors, and important biomarkers and pathways in myelofibrosis.

Polycythemia Vera: Prognosis and Risk for Progression to Myelofibrosis

March 29th 2023

Panel experts share insight regarding prognosis for patients with polycythemia vera and the associated risk for progression to myelofibrosis.

FDA Issues Complete Response Letter for Ruxolitinib Extended-Release Tablets in MPNs

March 24th 2023

The FDA has issued a complete response letter for ruxolitinib extended-release tablets for use once daily in the treatment of patients with certain types of myelofibrosis, polycythemia vera, and graft-vs-host disease.

Emerging Data Offer Alternatives for Patients With Lower-Risk MDS

March 23rd 2023

Frontline treatments that achieve transfusion independence are of paramount importance for patients with lower-risk myelodysplastic syndrome.